These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

386 related items for PubMed ID: 16105846

  • 21. Dual blockade of the renin-angiotensin system in the progression of renal disease: the need for more clinical trials.
    Fernandez-Juárez G, Barrio V, de Vinuesa SG, Goicoechea M, Praga M, Luño J.
    J Am Soc Nephrol; 2006 Dec; 17(12 Suppl 3):S250-4. PubMed ID: 17130270
    [Abstract] [Full Text] [Related]

  • 22. Dual renin angiotensin system blockade in patients with acute myocardial infarction and preserved left ventricular systolic function.
    Suşan M, Petrescu L, Riviş AI, Suşan RM, Burghină D, Dan R, Cozma D, Drăgulescu SI.
    Rom J Intern Med; 2005 Dec; 43(3-4):187-98. PubMed ID: 16812979
    [Abstract] [Full Text] [Related]

  • 23. Dual blockade of the renin-angiotensin system in diabetic nephropathy.
    Wade VL, Gleason BL.
    Ann Pharmacother; 2004 Dec; 38(7-8):1278-82. PubMed ID: 15187210
    [Abstract] [Full Text] [Related]

  • 24. Angiotensin II receptor blockers and cardiovascular outcomes: what does the future hold?
    Weber MA.
    J Renin Angiotensin Aldosterone Syst; 2003 Jun; 4(2):62-73. PubMed ID: 12806587
    [Abstract] [Full Text] [Related]

  • 25. Angiotensin-converting enzyme inhibitors (ACEIs), not angiotensin receptor blockers (ARBs), are preferred and effective mode of therapy in high cardiovascular risk patients.
    Vijan SG.
    J Indian Med Assoc; 2009 Mar; 107(3):178-82. PubMed ID: 19810392
    [Abstract] [Full Text] [Related]

  • 26. The effect of valsartan, captopril, or both on atherosclerotic events after acute myocardial infarction: an analysis of the Valsartan in Acute Myocardial Infarction Trial (VALIANT).
    McMurray J, Solomon S, Pieper K, Reed S, Rouleau J, Velazquez E, White H, Howlett J, Swedberg K, Maggioni A, Køber L, Van de Werf F, Califf R, Pfeffer M.
    J Am Coll Cardiol; 2006 Feb 21; 47(4):726-33. PubMed ID: 16487836
    [Abstract] [Full Text] [Related]

  • 27. [Inhibition of the renin-angiotensin system: ACE inhibitors and angiotensin II receptor blockers].
    Pichler M, Klein W, Huber K, Pachinger O.
    Wien Med Wochenschr; 1996 Feb 21; 146(11):228-31. PubMed ID: 8928520
    [Abstract] [Full Text] [Related]

  • 28. [ACE inhibitors and angiotensin II receptor antagonists in acute coronary syndrome].
    Milicić D.
    Acta Med Croatica; 2004 Feb 21; 58(2):129-34. PubMed ID: 15208798
    [Abstract] [Full Text] [Related]

  • 29. Blockade of renin-angiotensin-aldosterone system in kidney and heart disease: how much do we need?
    Lim S.
    Acta Med Indones; 2008 Jan 21; 40(1):34-7. PubMed ID: 19054878
    [Abstract] [Full Text] [Related]

  • 30. Angiotensin II receptor blockers and myocardial infarction: an updated analysis of randomized clinical trials.
    Volpe M, Tocci G, Sciarretta S, Verdecchia P, Trimarco B, Mancia G.
    J Hypertens; 2009 May 21; 27(5):941-6. PubMed ID: 19381108
    [Abstract] [Full Text] [Related]

  • 31. [Hypertension 2007-2008].
    Chatzikyrkou C, Menne J, Haller H.
    Med Klin (Munich); 2009 Aug 21; 104(8):614-21. PubMed ID: 19701732
    [Abstract] [Full Text] [Related]

  • 32. Angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers for prevention and treatment of nephropathy associated with type 2 diabetes mellitus.
    Hughes DB, Britton ML.
    Pharmacotherapy; 2005 Nov 21; 25(11):1602-20. PubMed ID: 16232022
    [Abstract] [Full Text] [Related]

  • 33. Current possibilities of ACE inhibitor and ARB combination in arterial hypertension and its complications.
    Kolasinska-Malkowska K, Filipiak KJ, Gwizdala A, Tykarski A.
    Expert Rev Cardiovasc Ther; 2008 Jun 21; 6(5):759-71. PubMed ID: 18510491
    [Abstract] [Full Text] [Related]

  • 34. [ACE inhibitor or ATII receptor blocker in heart failure and myocardial infarction?].
    Landmark K, Reikvam A.
    Tidsskr Nor Laegeforen; 2005 Jan 06; 125(1):38-40. PubMed ID: 15643463
    [Abstract] [Full Text] [Related]

  • 35. AT1 receptor blockade for the prevention of cardiovascular events after myocardial infarction.
    Azadpour M, Lamas GA.
    Expert Rev Cardiovasc Ther; 2004 Nov 06; 2(6):891-902. PubMed ID: 15500434
    [Abstract] [Full Text] [Related]

  • 36. Differential effects of RAS inhibitors associated with ACE gene polymorphisms in type 2 diabetic nephropathy.
    Seki N, Hashimoto N, Suzuki Y, Yagui K, Saito Y.
    Diabetes Res Clin Pract; 2006 May 06; 72(2):135-41. PubMed ID: 16290123
    [Abstract] [Full Text] [Related]

  • 37. Angiotensin receptor blockers versus ACE inhibitors: prevention of death and myocardial infarction in high-risk populations.
    Epstein BJ, Gums JG.
    Ann Pharmacother; 2005 Mar 06; 39(3):470-80. PubMed ID: 15701766
    [Abstract] [Full Text] [Related]

  • 38. Renin angiotensin system blockade and cardiovascular outcomes in patients with chronic kidney disease and proteinuria: a meta-analysis.
    Balamuthusamy S, Srinivasan L, Verma M, Adigopula S, Jalandhara N, Hathiwala S, Smith E.
    Am Heart J; 2008 May 06; 155(5):791-805. PubMed ID: 18440325
    [Abstract] [Full Text] [Related]

  • 39. Prescribing angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in chronic kidney disease.
    Ferrari P.
    Nephrology (Carlton); 2007 Feb 06; 12(1):81-9. PubMed ID: 17295666
    [Abstract] [Full Text] [Related]

  • 40. Will more complete inhibition of the RAAS with angiotensin receptor blockade improve survival following myocardial infarction?
    Pfeffer MA.
    J Renin Angiotensin Aldosterone Syst; 2000 Jun 06; 1(2 Suppl):S41-3. PubMed ID: 17199221
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 20.